Akari Therapeutics Plc

AKTX Nasdaq SEC CIK 1541157
Follow Akari Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$4.8M +24.3% vs same quarter last year
EPS, diluted $0.00
Operating cash flow −$4.2M −99.2% vs same quarter last year
Operating income −$4.7M +36.8% vs same quarter last year
Net income by quarter
−$3.8M
−$3.7M
−$1.9M
−$6.4M
−$5.3M
−$14.5M
−$4.8M
−$4.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$17.3M
FY24−$19.8M
FY23−$10M
FY22−$13.1M
FY21−$17.4M
FY20−$17.1M
FY19−$16.8M
FY18−$20.5M
FY17−$35.4M
FY16−$18.1M
FY15−$45.3M
FY14−$1.9M
FY13−$3.6M
FY12−$4.3M
FY11−$2.1M
Free cash flowOperating cash flow minus capital expenditure
−$40M−$30M−$20M−$10M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23−$16.4M
FY22−$7.6M
FY21-
FY20-
FY19−$12.9M
FY18−$22.8M
FY17−$31.6M
FY16−$24.7M
FY15−$5M
FY14−$1.5M
FY13−$5.5M
FY12−$2.1M
FY11−$1M